文献速递肝病消化道肿瘤与早癌

全民乙型肝炎病毒疫苗接种大幅降低乙型肝炎病毒感染患病率及肝细胞癌发病率

Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2022-07-21

该研究为全港回顾性观察性队列研究,纳入1970—2002年出生且检测过乙型肝炎表面抗原的成年人。疫苗接种队列(1988—2002年出生)与未接种队列(1970—1987年出生)相比,慢性乙型肝炎病毒感染患病率从1970年出生者的14.3%降至1988年出生者的6.7%;接种者肝细胞癌和肝脏事件发生率在调整后数值上较低,但因发生率极低未达统计学显著。

要点

  • 慢性乙型肝炎病毒感染患病率从1970年出生者的14.3%降至1988年出生者的6.7%。
  • 接种队列肝细胞癌发生44例(0.1%),未接种队列1305例(0.4%)。
  • 接种队列肝脏事件发生75例(0.1%),未接种队列1806例(0.6%)。

核心结论

  • 全民乙型肝炎病毒疫苗接种显著降低慢性乙型肝炎病毒感染患病率,并可能有助于降低肝细胞癌和肝脏事件的发生率。

研究设计与样本

  • 全港回顾性观察性队列研究,连续纳入1970—2002年出生且检测过乙型肝炎表面抗原的成年人;1988—2002年出生者纳入接种队列,1970—1987年出生者纳入未接种队列。

主要发现

  • 乙型肝炎病毒感染患病率分析纳入695925名受试者,慢性乙型肝炎病毒感染患病率从1970年出生者的14.3%降至1988年出生者的6.7%。
  • 事件分析纳入有临床数据的53960名接种者和318290名未接种者;接种者肝细胞癌发生44例(0.1%),未接种者1305例(0.4%)。
  • 接种者肝脏事件发生75例(0.1%),未接种者1806例(0.6%)。
  • 调整年龄、性别和抗病毒治疗后,接种者所有发生率数值上仍低于未接种者,但因发生率极低未达统计学显著。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Universal vaccination of newborns with hepatitis B virus (HBV) vaccine is the most important strategy to prevent chronic HBV infection and its complications of which hepatocellular carcinoma (HCC) as the deadliest. AIMS: To evaluate the impact of universal HBV vaccination on the prevalence of chronic HBV infection, and the incidences of HCC and hepatic events in young adults born before and after the introduction of the universal HBV vaccination programme in 1988 in Hong Kong METHODS: This was a territory-wide retrospective observational cohort study of consecutive adult subjects born in 1970-2002 with hepatitis B surface antigen (HBsAg) checked. Subjects born during the vaccination era (1988-2002) were included in the vaccinated cohort; subjects born between 1970 and 1987 were included in the unvaccinated cohort. RESULTS: We included 695,925 subjects for HBV prevalence analysis. Chronic HBV infection dropped from 14.3% in subjects born in 1970, to 6.7% in subjects born in 1988. In total, 53,960 vaccinated and 318,290 unvaccinated subjects who had available clinical data were included for event analysis. HCC and hepatic events occurred in 44 (0.1%) and 75 (0.1%) of the vaccinated subjects and in 1305 (0.4%) and 1806 (0.6%) of the unvaccinated subjects, respectively. All incidence rates remained numerically lower in vaccinated subjects after adjustment for age, gender and antiviral treatment, but failed to reach statistical significance due to very low incidence rates. CONCLUSIONS: Universal HBV vaccination markedly reduces the prevalence of chronic HBV infection and may contribute to the decreased incidences of HCC and hepatic events.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wong GL, Hui VW, Yip TC, et al. Universal HBV vaccination dramatically reduces the prevalence of HBV infection and incidence of hepatocellular carcinoma. Aliment Pharmacol Ther. 2022. PMID: 35864571. doi:10.1111/apt.17120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。